Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway

Gerlinde Holeiter1, Johanna Heering, Patrik Erlmann

  • 1Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.

Cancer Research
|November 1, 2008
PubMed

Insights

Loss of Deleted in liver cancer (DLC) 1 in breast cancer cells enhances migration by stabilizing cell structures. DLC1, unlike DLC2, is crucial for controlling Rho signaling and cell movement.

Area of Science:

  • Cell Biology
  • Cancer Research
  • Molecular Biology

Background:

  • Deleted in liver cancer (DLC) 1 and 2 are Rho GTPase-activating proteins often downregulated in cancers.
  • Previous studies showed ectopic expression inhibits cancer cell migration and invasion.

Purpose of the Study:

  • To investigate if DLC1 or DLC2 loss causes aberrant Rho signaling in transformed cells.
  • To determine the specific roles of DLC1 and DLC2 in breast cancer cell migration.

Main Methods:

  • RNA interference was used to down-regulate DLC1 and DLC2 expression in breast cancer cells.
  • Cell motility was assessed using wound-healing and Transwell assays.
  • The involvement of Rho effector proteins was analyzed.

Main Results:

  • DLC1 silencing stabilized stress fibers and focal adhesions, enhancing cell motility.
  • Enhanced migration in DLC1-deficient cells depended on Dia1 but not Rho kinase.
  • DLC2 knockdown did not affect cell migration, indicating distinct functions.

Conclusions:

  • DLC1 critically controls Rho signaling and actin cytoskeleton remodeling.
  • Loss of DLC1 is sufficient to promote a migratory phenotype in breast cancer cells.
  • Differential subcellular localization (DLC1 in focal adhesions, DLC2 cytosolic) likely explains distinct functions.